Harmony Biosciences(HRMY)

PLYMOUTH MEETING, PABiotechnology37 H-1B visas (FY2023)

Focus: Harmony Biosciences is a public biotech company focused on sleep and CNS disorders, generating $582M in FY2025 revenue primarily from a single marketed product. The company operates as a specialty pharma player with strong profitability and a defined pipeline expansion strategy.

Neurology

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

9-7 this month

Cooling — net -7 jobs in 30d

6 added, 13 removed. Slower than typical.

Should You Work at Harmony Biosciences?

AI assessment

Harmony is a high-cash, high-risk specialty biotech attractive for near-term stability and commercial growth, but career longevity depends entirely on pipeline success and WAKIX lifecycle extension before 2030 LOE.

Why Work Here

Strong cash generation ($453M cash position, $129M net income in FY2025) provides job security and investment in growth initiatives

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

1 in 5yr

WAKIX

Hiring

Stable

Revenue

$582M

Key Products

WAKIX

Narcolepsy with cataplexy and related sleep disorders

$101M Part D

Peak

Help build intelligence for Harmony Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Aggressive hiring stance (16 active roles, 100% H1B approval rate in 2023) signals expansion and career advancement opportunities

Leadership in rare sleep disorders and CNS space with multiple Phase 3 programs (pitolisant in idiopathic hypersomnia, Prader-Willi syndrome; clemizole in Dravet/Lennox-Gastaut) offers meaningful therapeutic impact

Watch Out For

Extreme revenue concentration—100% dependent on WAKIX with patent expiration in 2030 creates structural vulnerability and potential restructuring risk within 5 years
Pipeline quality is mixed; while 6 Phase 3 programs exist, many are line extensions of pitolisant or non-traditional programs (behavioral interventions, dietary supplements), reducing diversification
Modest R&D spending at 13% of revenue limits drug discovery firepower relative to peers; company is bet-the-farm on WAKIX extension strategy

Generated by Claude from Harmony Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Sole revenue driver representing 100% of company sales; in peak commercial phase with 5-year LOE window creating urgent need for pipeline succession.

Pipeline & Clinical Trials

Nasopharyngeal swabs

Influenza

N/A

Collection of stool samples

Healthy

N/A

Clinical Trials (1)

NCT03188302Evaluation of New Method for Measuring Stool Consistency

N/A

SOS Meditation

Healthy

N/A

Clinical Trials (1)

NCT06014281Examining the Effects of Regular Brief Internet-based Meditation Practice on Mental Health and Well Being

N/A

ACT Intervention Group

Child Abuse

N/A

Clinical Trials (1)

NCT07047378ACT-Based Training for Parental Burnout and Child Well-being

N/A

Nature-based intervention

Dementia

N/A

Clinical Trials (1)

NCT06451978You, Me and Nature Pilot Study

N/A

Singing

Dementia

N/A

Clinical Trials (1)

NCT06880237Sing Out Loud: a Choral Singing Program for Persons Living with Dementia

N/A

18 Test Products along with positive and negative control

Normal

N/A

Clinical Trials (1)

NCT07109453To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects

N/A

Music therapy

Palliative Care

N/A

Clinical Trials (1)

NCT02791048Music Therapy for Palliative Care Patients

N/A

Dietary Supplement: Complex with Biotin 5,000 mcg, Collagen, Keratin, Hyaluronic Acid.

Hair Thinning

N/A

Clinical Trials (1)

NCT07520019Study Evaluating the Effect of Nutra Harmony "Biotin, Collagen and Keratin Beauty Complex" Dietary Supplement on Hair Thickness and Hair Strength in Adults With Self-Perceived Thinning Hair

N/A

Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.

Hair Thinning

N/A

Clinical Trials (1)

NCT06605768Study Evaluating the Effects of Dietary Supplement on Hair Thickness and Hair Strength in Individuals With Self-Perceived Thinning Hair

N/A

Pitolisant

Pregnancy Related

N/A

Clinical Trials (1)

NCT05536011WAKIX® (Pitolisant) Pregnancy Registry

N/A

Pitolisant

Narcolepsy Without Cataplexy

N/A

Clinical Trials (1)

NCT03433131Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

N/A

Dance for PD®

Parkinson Disease

N/A

Clinical Trials (1)

NCT06220084The UPbeating GReek Application of DancE in Parkinson's Disease Clinical Trial

N/A

Part 1

Drug Interaction

PHASE_1

Clinical Trials (1)

NCT06930872Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates

Phase 1

HBS-201

Narcolepsy

PHASE_1

Clinical Trials (1)

NCT07051252A Study of HBS-201 (Pitolisant Delayed-release)

Phase 1

MV-LASV

Lassa Virus Infection

PHASE_1

Clinical Trials (1)

NCT04055454A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Phase 1

ZYN002

22Q11.2 Deletion Syndrome

PHASE_2

Clinical Trials (1)

NCT05149898Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

Phase 2

OVX836 480µg

Influenza

PHASE_2

OVX836 shot

Vaccine-Preventable Diseases

PHASE_2

Pitolisant Oral Tablet

Myotonic Dystrophy 1

PHASE_2

Clinical Trials (1)

NCT04886518Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Phase 2

Pitolisant oral tablets

Prader-Willi Syndrome

PHASE_2

Clinical Trials (1)

NCT04257929A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Phase 2

Clemizole HCl

Lennox Gastaut Syndrome

PHASE_3

Clinical Trials (1)

NCT05066217An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

Phase 3

Pitolisant tablet

Prader-Willi Syndrome

PHASE_3

Clinical Trials (1)

NCT06366464A Study of Pitolisant in Patients With Prader-Willi Syndrome

Phase 3

Pitolisant

Prader-Willi Syndrome

PHASE_3

Clinical Trials (1)

NCT07219485A Study of Pitolisant in Participants With Prader-Willi Syndrome

Phase 3

Pitolisant

Idiopathic Hypersomnia

PHASE_3

Clinical Trials (1)

NCT05458128A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

Phase 3

Open-label pitolisant

Idiopathic Hypersomnia

PHASE_3

Clinical Trials (1)

NCT05156047A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Phase 3

Clemizole HCl

Dravet Syndrome

PHASE_3

Clinical Trials (1)

NCT04462770A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Phase 3

Pitolisant

Restless Legs Syndrome

PHASE_4

Clinical Trials (1)

NCT05581576Pitolisant in Refractory Restless Legs Syndrome

Phase 4

HBS-301 tablet

Idiopathic Hypersomnia

Phase 3

Clinical Trials (1)

NCT07500090A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

Phase 3

Interview Prep Quick Facts

Portfolio: 1 approved product, 26 clinical trials

Top TAs: Neurology

H-1B (2023): 37 approvals

SEC Filings: 2 available

Open Roles: 9 active jobs

Portfolio Health

Peak1 (100%)

1 total products

Therapeutic Area Focus

Neurology

3 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$582M33%

R&D Spend

$76M(13%)7%

Net Income

$129M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Harmony Biosciences(HRMY)

Should You Work at Harmony Biosciences?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (9)

Specialty Territory Manager - South, Tampa

Specialty Territory Manager - West, Los Angeles South

Associate Director, Clinical Safety & Pharmacovigilance

Specialty Territory Manager - Mid Atlantic, Charlottesville

Associate Director, Formulation Development

Executive Director, Commercial Analytics

Senior Manager, Clinical Operations

Associate Director, Corporate Counsel - Contracts

Specialty Territory Manager - Central, Memphis

Financials (FY2025)

Hiring Trend

Visa Sponsorship